+AA
Fr
Back
Evidence Summary

What is an Evidence Summary?

Key messages from scientific research that's ready to be acted on

Got It, Hide this
  • Rating:

In people with rheumatoid arthritis, some doses of biologic drugs increase serious infection

Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258-65.

Review question

In people with rheumatoid arthritis, do biologic disease-modifying antirheumatic drugs (biologics) increase serious infections compared with traditional disease-modifying antirheumatic drugs (DMARDs)?

Background

Rheumatoid arthritis is a chronic condition that causes inflammation of the small joints, usually in the hands and feet. Treatment focuses on controlling symptoms (pain and swelling) and preventing joint damage. Doctors will usually start by prescribing drugs that have the fewest side-effects; if they don’t work well, they move onto different types of drugs or combinations of drugs. Biologics are a fairly new type of drug that is prescribed for people who do not respond to DMARDs or who have had side-effects from DMARDs.

How the review was done

The researchers did a systematic review, including studies up to February 2014. They found 106 randomized controlled trials that included 42,330 adults with rheumatoid arthritis.

Any dose or combination of a variety of biologics (e.g., etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, anakinra, tocilizumab, abatacept, or rituximab) was compared with a traditional DMARD (including methotrexate).

Trials were combined using a type of analysis that lets you compare treatments even if they were not compared directly in the individual trials.

The main results were for standard-, high-, and low-doses of biologics or a combination of biologics (given with or without DMARDs) compared with treatment with one DMARD.

What the researchers found

45 trials had low risk for bias.

Compared with treatment with one DMARD:

  • treatment with a standard or high dose of biologics increased the risk of serious infections;
  • treatment with a combination of biologics increased the risk of serious infections; and
  • treatment with a low dose of biologics did not differ for serious infections.

Conclusion

In people with rheumatoid arthritis, standard- and high-dose, but not low-dose, biologic drugs increase the risk of serious infection compared with treatment with one traditional disease-modifying antirheumatic drug.

Biologic treatment (with or without a DMARD*) vs single DMARD treatment in people with rheumatoid arthritis

Treatment (given with or without a DMARD)

Absolute risk of serious infection per year compared with treatment with a single DMARD†

Standard-dose biologic

6 more serious infections per 1000 patients

High-dose biologic

17 more serious infections per 1000 patients

Combination of more than one biologic

55 more serious infections per 1000 patients

Low-dose biologic

No increase in the number of serious infections

*DMARD = disease-modifying antirheumatic drug.

†Absolute risk of serious infection per year with a single DMARD was 20 infections for every 1000 patients.




Glossary

Randomized controlled trials
Studies where people are assigned to one of the treatments purely by chance.
Systematic review
A comprehensive evaluation of the available research evidence on a particular topic.

Related Web Resources

DISCLAIMER These summaries are provided for informational purposes only. They are not a substitute for advice from your own health care professional. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the McMaster Optimal Aging Portal (info@mcmasteroptimalaging.org).

Register for free access to all Professional content

Register
Want the latest in aging research? Sign up for our email alerts.
Subscribe
© 2012 - 2019 McMaster University | 1280 Main Street West | Hamilton, Ontario L8S4L8 | +1 905-525-9140 | Terms Of Use